FAM13A

Across TCGA pan-cancer cohorts, FAM13A RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of FAM13A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FAM13A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FAM13A is over-expressed in tumor, although a few such as THCA and LIHC show the opposite, repressed pattern.

KIRC, THCA, and LIHC are the cancer types where FAM13A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM13A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+1.053	<.001	12	view →
THCA	Male	III,IV	−1.598	<.001	11	view →
LIHC	Female	II,III,IV	−1.733	<.001	9	view →
COAD	Female	All	−0.753	.003	8	view →
BRCA	All	III,IV	−2.218	<.001	6	view →
LUSC	All	II,III,IV	−0.782	<.001	6	view →
KIRP	Male	All	−0.592	.003	6	view →
PAAD	All	All	+0.815	.009	4	view →
CHOL	All	All	−1.765	<.001	3	view →
STAD	All	All	−0.605	.013	3	view →
UCEC	All	All	−0.923	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

FAM13A–KIRC

Open the KIRC breakdown →